Ronald Rogers, a spokesman for Fosamax manufacturer Merck & Co. Inc., called the Fosamax-fibrillation association an "old issue." He also pointed to an article published earlier this year in the British Medical Journal that found no such association.
Rogers also pointed out that the current study is an observational one and therefore subject to limitations not seen in a previous randomized trial. That trial saw an increase in the incidence of "serious" atrial fibrillation among Fosamax patients, he said, but it did not reach a statistically significant difference.
More information
There's more on type 2 diabetes at the American Diabetes Association.
